DelveInsight has launched a new report on “Coccidioidomycosis – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Coccidioidomycosis – Market Insights, Epidemiology, and Market Forecast-2030″report delivers an in-depth understanding of the Coccidioidomycosis, historical and forecasted epidemiology as well as the Coccidioidomycosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Coccidioidomycosis Market Report:
A study said the incidence of coccidioidomycosis increases steadily with age, with those over age 70 experiencing the highest rate at 209 cases per 100,000 population while the rate for those between 1 and 4 years of age is 7.7 per 100,000 population.
As per the study, there were 1,222 ill non-US-resident travelers with 1,393 diagnoses recorded during the 20-year analysis period. The median age was 40 (range 0–86 years); 52% were female. Patients were visited from 63 countries and territories, most commonly Canada (31%), Germany (14%), France (9%), and Japan (7%).
Key benefits of the report:
Coccidioidomycosis market report covers a descriptive overview and comprehensive insight of the Coccidioidomycosis Epidemiology and Coccidioidomycosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Coccidioidomycosis market report provides insights on the current and emerging therapies.
Coccidioidomycosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Coccidioidomycosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Coccidioidomycosis market.
Coccidioidomycosis (also known as Valley Fever) is an infection usually caused by inhaling the spores (“seeds”) of either Coccidioides immitis or Coccidioides posadasii fungi. These spores are found in the soil in certain geographic areas (called endemic) and get into the air when the soil is disturbed. Coccidioidomycosis cannot be passed from person-to-person.
There are three forms of Coccidioidomycosis i.e. acute pulmonary coccidioidomycosis, chronic pulmonary coccidioidomycosis, and disseminated coccidioidomycosis. Disseminated coccidioidomycosis, is the most severe form of the disease and occurs in about 1% of all cases, usually in people who have a poor immune system or pregnant women. This form can spread to the nervous system, bones, joints, or skin.
The dynamics of the Coccidioidomycosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Scynexis, Mycovia Pharmaceuticals, F2G, Amplyx Pharmaceuticals, and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Coccidioidomycosis Market Landscape
Coccidioidomycosis Pipeline Therapies and Key Companies
VT-1598: Mycovia Pharmaceuticals
Fosmanogepix: Amplyx Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Coccidioidomycosis Patient Share (%) Overview at a Glance
5. Coccidioidomycosis Market Overview at a Glance
6. Coccidioidomycosis Disease Background and Overview
7. Coccidioidomycosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Coccidioidomycosis
9. Coccidioidomycosis Current Treatment and Medical Practices
10. Unmet Needs
11. Coccidioidomycosis Emerging Therapies
12. Coccidioidomycosis Market Outlook
13. Country-Wise Coccidioidomycosis Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Coccidioidomycosis Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Coccidioidomycosis Market Outlook 2030
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States